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ABSTRACT
Harboring the apolipoprotein E4 (APOE4) allele is the greatest genetic risk factor
associated with late-onset (sporadic) Alzheimer’s disease (AD), however the mechanism
by which apoE4 contributes to the pathology of AD is unknown. The proteolysis of
apoE4 has been suggested to contribute to AD pathology due to a possible toxic gain, or
loss of function. In order to determine if apoE4 is being cleaved, we designed and
characterized a site-directed cleavage antibody directed at position D151 of full length
human apoE4. The antibody (nApoECFp17) detected a predicted ~17 kDa fragment
following incubation with the proteases Type-1 collagenase, and matrix
metalloproteinase (MMP)-1and 9. Once the nApoECFp17 amino-terminal antibody was
applied to frontal cortex AD brain sections, it revealed nuclear labeling of glial cells and
neurofibrillary tangles (NFTs). In addition, nApoECFp17 regionally localized with the
protease MMP-9 in plaque-rich regions in vivo, suggesting apoE4 may be cleaved
extracellularly. Together these data suggest a novel cleavage event of apoE4 by Type-I
collagenase and MMP-1 and 9, generating an amino-terminal fragment that is then taken
up by glial cells and localizes to the nucleus. This fragment localizing to the nucleus
purposes a new role of apoE4 in AD pathology where apoE may alter gene expression.
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INTRODUCTION
Although the first case of Alzheimer’s disease (AD) was described more than 100
years ago, there is still no cure or any effective treatments for this disease. It is known
that AD is pathologically characterized by the presence of beta amyloid plaques (Aβplaques) and neurofibrillary tangles (NFTs). Current dogma suggests that Aβ formation
precedes the formation of NFTs and collectively has become known as the Amyloid
Cascade Hypothesis. Current AD research is focused on either targeting the initial
formation of Aβ-plaques, and/or how Aβ-plaques and NFTs cause their toxic effects in
the brain. The focus of my thesis investigates the role of apolipoprotein E (apoE)
proteolysis in promoting AD pathology. The proteolysis of apoE may drive AD
pathology by either gaining a new toxic function, losing its normal function, or both. Due
to the possible loss and/or gain of function following proteolysis of apoE, the research
conducted in this work focuses on apoE’s production of a toxic fragment that may
influence NFT and Aβ-plaque formation.
The Brain
The brain is a very complex organ both in structure and function in the human
body. The brain connects us with our world by allowing us to interact with sensory
stimuli. It is vital in connecting us with one another by processing language and emotion.
Most importantly, the cerebral cortex of the brain is responsible for many of the higher
executive functions that contribute to distinguishing humans from other species. The
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brain is a very powerful organ of which we have only scratched the surface in
discovering its true capabilities.
The human central nervous system consists of the brain and spinal cord. Through
a network of nerve cells and connections, information from the central nervous system is
distributed throughout the body. The brain is composed of grey matter (cell bodies,
dendrites, and axon terminals of neurons) and white matter (axons that connect parts of
the grey matter together), which is encased in a bony structure called the cranium. The
brain consists of two cell types, neurons and glial cells. Neurons are specialized cells that
transmit nerve impulses, and are the fundamental units of the nervous system. The
structure of a neuron consists of a central cell body housing the nucleus, an axon for
signal transduction, and dendrites for receiving information. The brain is composed of
roughly 100 billion neurons, however, there are 10-50 times that number of glial cells in
the human brain. Unlike the communication functionality of neurons, glial cell function is
to protect and support neurons. Glial cells provide oxygen, insulation, hold neurons in
place, and clean up cellular debris. There are three types of glial cells; 1) astrocytes,
which are star-like cells that link neurons to blood vessels 2) oligodendrocytes, which
support and insulate axons and 3) microglia, which are systemically analogous to white
blood cells.
Alzheimer’s Disease
Alzheimer’s disease (AD) is a progressive, irreversible neurodegenerative disease
characterized by neuronal death and synaptic pruning [1]. AD is the most common form
of dementia and results in memory deficits, language difficulties, impairment of
visuospatial abilities, as well as other cognitive impairments [2]. Currently, AD affects

3
over 5 million people in the United States alone and annually costs the national
healthcare system over 243 billion dollars. The high cost to care for those afflicted with
AD emphasizes the importance of discovering preventative strategies, and effective
treatments in hopes of a cure.
Currently, the mechanisms associated with AD pathology are unclear. However,
the involvement of Aβ plaques appear to be central in leading to neuronal degeneration.
Aβ plaques are insoluble aggregates of the amyloid β peptide that collect in the brain
parenchyma surrounding neurons and glial cells. Production of Aβ results from the
proteolysis of the amyloid precursor protein (APP) by either α, β, or γ secretases [3]. The
β secretase cleaves APP, resulting in a soluble amino terminal fragment containing
extracellular sequences of APP. However, cleavage of APP by the α secretase results in a
soluble amino terminal fragment, as well as a carboxyl-terminal membrane bound
fragment. The γ secretase can further cleave the membrane-bound carboxyl-terminal
fragment or the amino-terminal fragments producing Aβ. The increase in Aβ leads to
induction of oxidative stress, apoptosis, and disrupted axonal transport, ultimately
resulting in defective cognitive ability and NFT pathology [3].
Research suggests the protein tau contributes to NFT formation in AD. Tau is a
microtubule associated protein (MAP) and is expressed in the neuronal axon. Tau
normally functions to stabilize the cytoskeleton by binding to microtubules and also plays
a role in anterograde transport in neurons and glial cells. Tau can be hyperphosphorylated
resulting in a decreased binding affinity to microtubules and subsequent aggregation of
tau into beta sheet structures termed paired helical filaments (PHFs), which then
aggregate as rope-like structures composed of two fibers twisted around one another [4].
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The loss of function of tau in AD decreases the ability of microtubules to bind to tubulin
for proper assembly and polymerization, increasing the occurrence of aggregating tau
binding to normal tau [5].
Alzheimer’s Disease Diagnosis and Treatment Strategies
Clinical diagnosis of AD is primarily made by exclusion of other causes of
dementia. A true diagnosis of AD can only be obtained by performing an autopsy with
post mortem tissue analysis [6]. Thus, there is a demand for biomarkers associated with
AD, not only for proper diagnosis, but also to determine susceptibility to AD and to
assess treatment strategies. Currently, there are no prevention measures that can be taken
for AD. Drugs on the market to aid with AD treatment are designed to maintain synapses
and overall neuron function. Examples of AD drug targets are: the hyperphosphorylation
of tau, NMDA receptor blockade, acetylcholinesterase inhibition or nicotinic receptor
agonists, and neurotransmitter balance [7]. Aside from the therapeutic approach to help
control symptoms of AD, disease modifying strategies are also under investigation aimed
at reducing Aβ levels in the brain and reestablishing tau function. In order to achieve this
goal, current gene therapy techniques such as lentiviruses or viral vectors are becoming
more popular [8], as well as cell replacement therapies [9]. Very new on the horizon is
analyzing the epigenetic component of AD, which could be useful for determining
biomarkers and predisposition [10].
Risk Factors in Alzheimer’s Disease
The greatest risk factor for AD is advancing age with current statistics indicating
that 11 percent of those age 65 and older and 32 percent of people age 85 and older are
afflicted with this disease [11]. There are two types of AD: early-onset familial AD
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(before age 65) and late-onset or sporadic AD. Early-onset AD is caused by mutations in
the amyloid precursor protein (APP) or presenilin-1 (PSEN 1) and presenilin-2 (PSEN 2)
genes. Mutations in these proteins ultimately enhance production of Aβ, which leads to
an increase in Aβ-plaque deposition. Additionally, the increase in plaque formation could
be due to a failure to remove or clear Aβ from the brain, contributing to AD pathogenesis.
Several genetic risk factors are also associated with late-onset AD such as A2M
(encoding alpha-2-macroglobulin), ABCA1 and 2 (encoding ATP-binding cassette
transporters 1 and 2, respectively), CLU (encoding clusterin), PICALM (encoding the
phosphatidylinositol binding clathrin assembly protein) and SORL1 (encoding sortilinrelated receptor gene) TREM2, and APOE4. There are two variants of TREM2 that
increase the risk of AD by three fold by either stimulating phagocytic activity or by
decreasing microglial pro-inflammatory responses [12]. However, the greatest genetic
risk factor is harboring the apolipoprotein E4 (APOE4) allele. The inheritance of one
copy of APOE4 increases the risk of AD four fold, while inheritance of two copies raises
the risk about tenfold. Despite the well-known risk associated with inheritance of the
APOE4 allele, the mechanism by which the apoE4 protein contributes to AD pathology
has not been definitively established.
APOE Structure and Function
Human apoE is polymorphic with three major isoforms, apoE2, apoE3, and
apoE4, which differ by a single amino acid substitution involving cysteine-arginine
replacements at positions 112 and 158 [13]. Harboring the APOE3 allele is believed to
neither increase nor decrease one’s risk of AD, having the E2 form may actually decrease
one’s risk, while having the E4 allele increases risk. Structurally, apoE4 is a 34 kDa
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protein composed of 299 amino acids and contains two major domains, referred to as the
N-terminal and C-terminal domains, which are connected by a short-hinge region [14] .
ApoE is expressed by astrocytes, some microglia, and in certain circumstances neurons
[15]. In the CNS, apoE functions to transport cholesterol to neurons through binding and
uptake by apoE low density lipoprotein (LDL) receptors [16]. Cholesterol released from
apoE-containing lipoprotein particles is used to support synaptogenesis and the
maintenance of synaptic connections [17]. Differences among apoE isoforms in these
processes may negatively impact synaptic plasticity or recovery of neurons from
neurodegeneration as might occur in AD [18].
Proteolysis of APOE
ApoE4 plays a normal role in lipoprotein transport in the brain, however the
mechanism by which apoE4 contributes to AD pathogenesis remains elusive. It has been
hypothesized that apoE4 is much more susceptible to proteolysis than the E2 or E3 form
due to the numerous proteolytic cleavage sites in the hinge region of apoE4 [19].
Although the hinge region is particularly susceptible to proteolysis, there is evidence to
support other susceptible regions of apoE4 such as the N-terminal and C-terminal
domains [20]. In mouse models, production of apoE by neurons is associated with apoE
fragmentation, whereas production of apoE by astrocytes is not [19]. Neuronal
proteolysis of apoE4 occurs preferentially in regions of the brain that are susceptible to
AD and neurodegeneration [21]. Additionally, proteolysis of apoE4 occurs to a greater
extent than for apoE3, and is associated with enhanced phosphorylation of tau [21]. There
are several studies that have demonstrated the presence of fragmented apoE4 in the AD
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brain [19, 21, 22], supporting the hypothesis that the proteolysis of apoE4 could
contribute to neuropathology and neurodegeneration in AD.
When apoE4 is cleaved, two distinct domains are produced and each are
associated with a specific pathological structure in the AD brain; the C-terminal domain
of apoE4 binds to beta amyloid and primarily localizes to plaques [22, 23], while the Nterminal domain mainly localizes to NFTs [19]. ApoE4 fragments produced by
proteolytic cleavage have been found to be associated with either a toxic gain of function
or a loss of normal function. Altered function of apoE4 due to the high susceptibility of
apoE4 to proteolysis may be responsible for the heightened risk associated with
inheritance of the APOE4 allele.
APOE Proteolysis Leads to a Loss of Function
The main function for apoE in the CNS is to transport cholesterol. As mentioned
previously, proteolysis of apoE occurs in neurons, not in astrocytes. In normal conditions,
neurons express very little apoE. However, expression of apoE is increased in neurons
under circumstances requiring neuronal repair, remodeling, and response to injury [24,
25]. ApoE may be providing the necessary cholesterol for neuronal repair as well as
synapse formation, plasticity, and repair [26]. The efficiency of apoE4 to transport
cholesterol and maintain neurons in response to injury may be reduced when compared
with the E2 and E3 isoforms and this could be due to lower levels of the apoE protein in
the brain following proteolysis of the protein [27].
In addition to the role of apoE in cholesterol transport, apoE also plays a role in
the clearance of Aβ deposition in the AD brain. It is hypothesized that apoE binds to Aβ
and induces a pathological β-sheet conformational change in Aβ [28]. Studies have
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reported that apoE3 and E2 form more stable complexes with Aβ and to a much greater
extent than E4 [29], and therefore, the better binding efficiency of apoE3 and E2 may
enhance Aβ clearance compared with apoE4 [30]. In a recent study, an AD mouse model
crossed with mice expressing C-terminal-truncated apoE4 showed these mice had a lower
affinity for beta amyloid and reduced ability to clear beta amyloid [31]. Additionally, the
APOE allele dosage is associated with increased plaque deposits in AD [32]. In a large
cerebrospinal fluid (CSF) study of cognitively normal middle-aged people (“at risk” for
AD), Aβ deposition was associated with low CSF levels of Aβ42 [34]. In carriers of the
APOE4 allele, lower CFS levels of Aβ42 were observed, emphasizing analysis of CSF
levels as pre-clinical detection tool for tracking of AD in “at risk” individuals [33].
APOE Proteolysis Leads to a Toxic Gain of Function
The proteolytic cleavage of apoE4 not only may lead to a loss of function, but it
may also produce a toxic-gain of function. The cleavage of apoE4 produces N- and Cterminal fragments that are neurotoxic in nature [22, 34, 35]. It has been hypothesized
that these fragments are generated following intraneuronal processing of apoE4 [22]. The
N-terminal fragment containing the receptor binding region of apoE4 (1-191) is
responsible for binding with tau [36] as well as the hyperphosphorylation of tau, a key
step in the evolution of NFTs [21]. The neurotoxicity of N-terminal fragments may also
promote the underlying pathology of AD by producing tangle-like inclusions, which are
similar to early NFTs both in vitro and in animal models [19, 34, 35]. The C-terminal
fragment containing the lipid- binding region (171-272) of apoE4 interacts with
mitochondria and C-terminal fragments have been shown to impair function and integrity
of mitochondria [34]. In addition, apoE4 fragments may lead to mitochondrial
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dysfunction by binding to mitochondrial proteins and enzymes and altering their
activities [37]. Another possible toxic gain of function involves oxidative stress. In this
regard, a specific fragment of apoE4 promotes cellular uptake of extracellular Aβ leading
to the formation of reactive oxygen species [38]. Finally, in a transgenic AD mouse
model, expression of a C-terminal-truncated fragment of apoE4 resulted in behavioral
deficits and a failure to clear Aβ deposition [31]. These results support the notion that
fragments produced from the proteolysis of apoE4 gain a toxic function and enhance the
underlying pathological mechanisms of AD.
Hypothesis
The exact nature of the protease involved in cleaving apoE4 is unknown although
several candidate proteases have been reported including cathepsin D [39], a
chymotrypsin-like protease [19], aspartic proteases [40], and caspases [23]. Previous
studies on the proteolysis of apoE4 in AD have identified the presence of a ~18 kDa band
in the human AD brain extracts, suggesting cleavage near position D154 of the mature
form of apoE4 (299 amino acids) [19, 22]. This site was chosen based on it being a
putative caspase consensus cleavage site. Rohn et al. synthesized and characterized a sitedirected cleavage antibody aimed at specifically recognizing this ~18 kDa fragment of
apoE4 found in AD samples. However, results indicated a protease other than caspase
was cleaving apoE4 at this site. Therefore, examination of an additional caspase-cleavage
consensus site with apoE4 was undertaken that would produce a slightly smaller aminoterminal fragment (~17 kDa) following putative cleavage of apoE4 by caspase-3 [23].
Thus, an additional site-directed antibody was designed to target position D151 just
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upstream of D154 [23], which will be referred to as nApoECFp17 for the duration of this
work.
Matrix metalloproteinases (MMPs) are a family of calcium-requiring and zinccontaining endopeptidases and evidence has suggested that MMPs may play an important
role in the pathogenesis of AD [41]. Type IV collagenase or MMP-9 is a major MMP that
is expressed and released by neurons, microglia, and astrocytes [42]. MMP-9 has also
been identified in neuroinflammation [42]. ApoE4 has been previously associated with
brain inflammation and AD patients with the E4 allele show increased microglial
activation compared with AD patients not carrying the E4 allele [43]. In a study
conducted by Dafinis et al., a particular apoE4 fragment lead to increased extracellular
levels of MMP-9 [38]. The hypothesis tested in my thesis is that full length apoE4 is a
target for proteolytic cleavage by MMP-9, resulting in a predicted ~17 kDa fragment and
this fragment is present in the AD brain.
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METHODS
Materials
Human recombinant apoE4 and E3 proteins purified from E. coli were purchased
from ProSci Inc. (Poway, CA). Activated human recombinant caspase-3 was purchased
from Calbiochem (San Diego, CA). The anti-apoE4 N-terminal full-length rabbit
polyclonal antibody was purchased from Aviva Systems Biology Corp. (San Diego, CA).
PHF-1 was a generous gift from Dr. Peter Davies (Albert Einstein College of Medicine,
Bronx, NY). Type I collagenase was from Sigma-Aldrich (St. Louis, MO) and purified
collagenase was from Worthington Biochemical (Lakewood, NJ). Active MMP-1 and the
mouse monoclonal MMP-9 antibody were purchased from Abcam Inc. (Cambridge,
MA), while active MMP-9 was purchased from EMD Millipore (Billerica, MA). The
monoclonal antibodies, Olig-1 and Iba1/AFI1, were purchased from EMD Millipore
(Billerica, MA).
Generation of the Polyclonal Site-Directed Cleavage Antibody to ApoE4
Synthesis of polyclonal antibodies was accomplished using the 7-mer peptide CRKRLLRD, which represents the N-terminal upstream neoepitope fragment of apoE4
generated following cleavage after the aspartic acid residue located at position D151 of
the mature form of apoE4. Following synthesis, this peptide was coupled to KLH and
injected into two rabbits. The resulting sera (verified by ELISAs, Fig. 2) were used to
affinity purify antibodies using a Sulfolink™ column (Thermo Scientific) coupled with
the peptide used as an immunogen. For this antibody, synthesis of peptides, injections of
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immunogens, and collection of antisera were contracted out to Bethyl laboratories
(Montgomery, TX).
ELISA
To verify the polyclonal site-directed cleavage antibody, 40µl of the N-terminal
neopeptide fragment of apoE4 following cleavage at position D151 was mixed with
coating buffer and added to 32 wells of a Dynex plate, covered, and incubated overnight
on a rocker at 4°C. TTBS (pH 7.5) was used to wash the plate after each incubation. 300
µl of blocking buffer was added to each well and was covered to incubate for 1 hour at
37° C. Dilutions of the pre-immunized and immunized sera ranged from 1:250- 1:32000.
The 1:250 dilution contained 4 µl of either pre-immunized or immunized serum and 996
µl of diluting buffer. Serial dilution was carried out until the 1:32000 dilution. After the
blocking stage, each dilution was added to the corresponding well and incubated for 2
hours at 37°C. The secondary antibody was a 1:5000 dilution of horseradish peroxidase
(HRP). The plate was washed and 100 µl of the secondary solution was added to each
well to incubate for 1 hour at 37°C. The plate was washed and 100 µl of TMB Microwell
Peroxidase substrate was added to each well. After 4 minutes, 100 µl TMB Stop solution
was added to each well. The plate was then read at a wavelength of 450 nm.
Cell-free assays/Western Blots
For the proteolysis of apoE4, 40 µg of purified human recombinant apoE4 was
incubated with active human recombinant caspase-3 at 37° C overnight in 2x reaction
buffer containing 10 mM DTT. Type I collagenase, purified collagenase, MMP-1, and 9
experiments were carried out utilizing a reaction buffer containing 100 mM Tris-HCL, 10
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mM CaCl₂, pH 7.8. The reactions were terminated by adding 5x sample buffer and were
stored at -20° C.
For Western blot analysis, samples were separated by 15% SDS PAGE (sodium
dodecyl sulfate polyacrylamide gel electrophoresis) and transferred to nitrocellulose.
Transferred gel slabs were stained in Coomassie blue to verify equal loading between
samples. Nitrocellulose membranes were incubated in nApoE4CF antibody (1:500)
overnight at 4°C and primary antibodies were visualized using goat anti-rabbit HRPlinked secondary antibody, incubated for 1 hour at room temperature (1:5,000; Jackson’s
Laboratory, West Grove, PA), followed by ECL detection.
Immunoprecipitation and Mass Spectrometry
Immunoprecipitation experiments were conducted by incubating the
nApoECFp17 antibody with apoE4 samples digested with Type I collagenase. To
terminate the actions of Type I collagenase, 100 mM EDTA (ethylenediamine tetra-acetic
acid) was added at the conclusion of the experiment. Samples were incubated overnight
at 4°C with nApoECFp17 antibody and then 50 µl of Protein A agarose beads were added
for 2 hours at 4°C. The agarose beads were then spun down and washed 3X in PBS.
Samples were prepared for Western blot analysis as described above utilizing a
commercial antibody that recognizes the extreme amino-terminus of full-length apoE4.
For mass spectrometry experiment samples were separated by 15% SDS PAGE
and gel slices were excised from SDS-PAGE gels and digested with trypsin. Briefly,
excised bands were destained in 25 mM ammonium bicarbonate/50% acetonitrile
overnight at 4°C. Gel slices were dehydrated in 100% acetonitrile for 10 minutes at room
temperature, followed by reduction in 10 mM DTT for 60 minutes at 37°C. Next,
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alkylation was performed in 55 mM iodoacetamide for 60 minutes at room temperature in
the dark. Protein samples were digested with trypsin in 10 mM ammonium bicarbonate
overnight at 30°C. Digested peptides were separated using reversed phase
chromatography (Thermo Scientific Easy-nLC II) and infused into a Velos Pro DualPressure Linear Ion Trap Mass Spectrometer for MS/MS using CID fragmentation.
Results were analyzed with Thermo Scientific’s Proteome Discoverer software (v1.3) and
the Mascot search engine probing the human SwissProt database. Search parameters
included carbamidomethyl (C) fixed modification, oxidation (M) variable modification,
maximum of 2 missed cleavages, and 1.5 Da peptide mass tolerance.
Human Subjects
Autopsy brain tissue from the frontal cortex of nine neuropathologically
confirmed AD cases with known apoE isoform genotype and three age-matched control
cases were studied. Fixed frontal cortex tissue sections used in this study were provided
by the Institute for Memory Impairments and Neurological Disorders at the University of
California, Irvine. Approval from Boise State University Institutional Review Board was
not obtained due to the exemption granted that all tissue sections were fixed and received
from University of California, Irvine. Brain tissue obtained from University of California,
Irvine were anonymized and never identified except by case number. Tissue donors or
their next of kin provided signed informed consents to the Institute for Memory
Impairments and Neurological Disorders for the use of their tissues in research (IRB
2014–1526). Case demographics are presented in Table 1.
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Immunohistochemistry
Free-floating 40 μm-thick serial sections were used for immunohistochemistry
and immunofluorescence as previously described above. For bright-field labeling,
sections were washed with 0.1 M Tris-buffered saline (TBS), pH 7.4, and then pretreated
with 3% hydrogen peroxide in 10% methanol to block endogenous peroxidase activity.
Sections were subsequently washed in TBS with 0.1% Triton X-100 (TBS-A) and then
blocked for thirty minutes in TBS-A with 3% bovine serum albumin (TBS-B). Sections
were further incubated overnight at room temperature with the antibodies at the described
concentrations above. Following two washes with TBS-A and a wash in TBS-B, sections
were incubated in anti-rabbit or mouse biotinylated anti-IgG (1 hour) and then in avidin
biotin complex (1 hour) (ABC, Elite Immunoperoxidase, Vector Laboratories,
Burlingame, CA, USA). The primary antibody was visualized using brown DAB
substrate (Vector Laboratories).
Immunofluorescence Microscopy
For immunofluorescence co-localization studies, experiments were initiated by
incubating in primary antibody overnight followed by application of the ABC, Elite
Immunoperoxidase kit on day 2 (Vector Laboratories, Burlingame, CA, USA). In this
case, instead of completing the staining use DAB substrate, we employed Alexa fluor
488-labeled tyramide (green, Ex/ Em=495/519) that was purchased as part of the TSA
(Tyramide signal amplification) kit #12 (Life technologies, Green Island, NY). Following
labeling with the primary antibody, sections were washed 3X in Tris buffer followed by
incubations in Tris A (15 minutes) and Tris B (30 minutes). Sections were then incubated
with the second primary antibody overnight at room temperature. On day 3, sections were
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incubated with secondary biotinylated-SP (long spacer) AffiniPuregoat anti-mouse or
rabbit IgG for 1 hour (Jackson Immuno Research Labs (West Grove, PA). This was
followed by incubation in streptavidin Alexa Fluor 555 conjugate for 1 hour (Life
technologies, Green Island, NY). Following 3X washes in Tris buffer, sections were
mounted and cover slipped using Pro-Long Gold Antifade with DAPI (Life
technologies). To determine if cross-reactivity to reagents was a factor in double-labeling
experiments, experiments were replicated with the antibodies in reverse.
An Olympus BX60 microscope with fluorescence capability equipped with a
MagnaFire SP software system for photomicrography was employed for microscopic
observation and photomicrography of the diaminobenzidine (DAB)-labeled and
fluorescent sections. The fluorescent molecules were excited with a 100-W mercury
lamp. Fluorescent-labeled molecules were detected using a filter set having a 460–500nm wavelength band pass excitation filter, a 505-nm dichroic beam splitter, and a 510–
560-nm band pass emission filter.
Confocal Microscopy
For confocal immunofluorescence imaging, the primary antibodies were
visualized with secondary antibodies tagged with either Alexa Fluor 488 or Alexa Fluor
555 (Invitrogen, Carlsbad, CA). Images were taken with a Zeiss LSM510 Metasystem
combined with the Zeiss Axiovert Observer Z1inverted microscope and ZEN2009
imaging software (Carl Zeiss, Inc., Thornwood, NY). Confocal Z-stack and single plane
images were acquired with an Argon (488 nm) and a HeNe (543 nm) laser source. Zstacks images were acquired using a 20x Plan-Apochromat (NA 0.8) objective, emission
band passes of 505–550 nm for the detection of the green channel, Alexa Fluor 488 and
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550–600 nm for detection of the red channel, Alexa Fluor 555. All images displayed are
2-D, maximal intensity projections generated acquired Z-stacks. Single plane images
were acquired with a 63x Plan-Apochromat oil-immersion objective (NA 1.4) with
emission long pass of 505 nm for the detection of the green channel using Alexa Fluor
488 and 550–600 nm for the detection of the red channel using Alexa Fluor 555.
Quantification and Statistical Analysis
Statistical difference between the average number of nApoE4CFp17-positive
NFTs in 3 AD cases from each allelic combination of ApoE3/ApoE3, ApoE3/ApoE4, and
ApoE4/ApoE4A was determined using Student’s two-tailed T-test. To determine the
percent co-localization, a semi-quantitative analysis was performed by taking 40X
immunofluorescence, overlapping images from three different fields in frontal cortex
brain sections of three separate AD cases. Capturing was accomplished by using a 2.5x
photo eyepiece and a Sony high resolution CCD (charged-coupled device) video camera
(XC-77). As an example, to determine the percent co-localization between Iba-1 and
nApoE4CFp17, photographs were analyzed by counting the total number of doublelabeled cells per 40X field for each case, and the number of cells labeled with each
antibody alone. Statistical differences in this study were determined using Student’s twotailed T-test employing Microsoft Office Excel.
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RESULTS
In a previous study, we identified a ~17 kDa band when incubating human
recombinant apoE with activated caspase-3 [23]. Based on results from that study, we
designed a site-directed cleavage antibody based on a caspase-cleavage recognition site at
position D151 (LLRD) of the full-length form of apoE4 that would give a predicted
amino-terminal fragment of ~17 kDa (Fig. 1). Following synthesis of a 7-mer peptide
RKRLLRD, this peptide was coupled to KLH and injected into rabbits. Peptide-specific
anitbodies were affinity purified from resulting sera, which was verified by ELISA (Fig.
2). Western blot analysis was performed to determine if nApoECFp17 could label the
predicted 17 kDa fragment following incubation with caspase-3. Figure 3A shows that
we were unable to detect any band following incubation of full-length apoE4 with
caspase-3. We hypothesized that since apoE4 is a secreted protein, any potential protease
would be located extracellularly, therefore we next tested collagenase. Incubation of
recombinant apoE4 with Type I collagenase generated a ~17 kDa fragment that was
detected by nApoECFp17 (Fig. 3A, second lane, left panel). The nApoECFp17 antibody
did not react with full-length apoE4, nor did the antibody detect any fragments following
incubation with recombinant apoE3 (Fig. 3A, left panel). To confirm the specificity of
nApoECFp17, we preformed immunoprecipitation experiments by incubating
nApoECFp17 with apoE4 that had been digested with Type I collagenase. The
nApoECFp17 antibody immunoprecipitated a ~17 kDa fragment that was detected by
Western blot using an apoE4 antibody whose epitope is at the extreme amino-terminus of
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apoE4 (Fig. 3B). Additionally, mass spectrometry of the 17 kDa band indicated 77%
sequence coverage of amino acids 1-151 of apoE4.
The Type I collagenase originally used was a bacterial collagenase preparation
that included collagenase, caseinase, clostripain, and tryptic activities. The experiments
were performed again using purified collagenase as well as MMP-9 and MMP-1 given
that the MMPs have a high degree of homology with collagenase. When apoE4 was
cleaved by purified collagenase, high molecular weight bands were produced that were
detected by nApoECFp17 (Fig. 3C, left panel). These high molecular weight bands
suggest that the cleavage of apoE4 may result in aggregation. Incubation of full-length
apoE4 with MMP-9 produced similar results as Type I collagenase, however, incubation
with MMP-1 produced a high-molecular weight band only when the concentration of
recombinant apoE4 was doubled (Fig. 3C, left panel). These results suggest
nApoECFp17 detects an amino-terminal fragment of apoE of ~17 kDa at the cleavage
site D151, and that MMP-9 can generate this fragment in vitro. In addition, Western blot
analysis following incubation of apoE3 with MMP-9 indicated that apoE3 is also
proteolyzed generating in this case only high molecular weight bands (Fig. 5).
To further test the specificity of the nApoECFp17 antibody, an amino-terminal
protein fragment of apoE4 was synthesized corresponding to the predicted length
following cleavage at D151. This amino-terminal fragment (herein termed apoE41-151)
also contained a 6X histidine (His) tag to facilitate purification from E. coli. In this
manner, the 6X His tag was attached either at the N-terminal end of apoE41-151 or to the
C-terminal end of apoE41-151. The addition of the His tag to this fragment greatly
influenced whether the nApoECFp17 antibody recognized the fragment. Thus, when the
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His tag was attached to the C-terminal end of apoE41-151, there was limited detection by
nApoECFp17 in either ELISA assays (Fig. 4A) or Western blot analysis (Fig. 4B). We
interpret these data to suggest that the addition of the His tag to the C-terminal end of
apoE41-151 prevented the nApoECFp17 from binding to its epitope on the C-terminal end
of the fragment. These data further support the specificity of the nApoECF-17 antibody
for the C-terminal region of apoE4 following cleavage at D151.
After Western blot analysis confirmed the cleavage of apoE4 in vitro,
immunohistochemical experiments were done using postmortem frontal cortex brain
sections from AD cases. In order to establish the staining profile of nApoECFp17
antibody labeling in AD brain sections, single label, bright-field experiments were carried
out. The results indicated immunoreactivity by the nApoECFp17 antibody in all AD
cases examined. The strongest labeling was in neurons (Fig. 6A and B), neuropil threads
(PHFs with abnormally phosphorylated tau protein) in plaque regions (Fig. 6C), blood
vessels (Fig 6D), and small circular structures in gray and white matter (Fig. 6E).
Additional experiments supported the specificity of the nApoECFp17 antibody
including a lack of staining observed following application of preimmune serum, and
preadsorption of the affinity-purified antibody with the immunogenic peptide, which
significantly reduced labeling in serial AD sections (Fig. 7A-D). In addition, there was no
staining of the nApoECFp17 antibody in aged matched controls, and when AD cases
were compared with normal cases, there was a significant increase in the number of
labeled nuclei in AD cases (p=0.0004) (Fig. 7E and F).
Due to the small size of the circular structures, we hypothesized that the labeling
was occurring in the nuclei of glia cells. To test the nuclear localization of nApoECFp17
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in glia cells, the glial markers Iba-1 (to detect microglia), Olig-1 (to detect
oligodendrocytes, and GFAP (Glial fibrillay acidic protein) (to detect astrocytes) were
used. In each case, 4’6-diamidino-2-phenylindole (DAPI) was used as the nuclear stain to
verify the staining that was being observed was nuclear. In Figure 8 A-D and I, the merge
of the staining of Iba-1, DAPI, and nApoECFp17 in representative frontal cortex AD
sections indicated approximately 80% of microglia were labeled by nApoECFp17
antibody. Additionally, the merge of Olig-1, DAPI, and nApoECFp17 indicated about
27% of oligodendrocytes were labeled with the nApoECFp17 antibody (Fig. 8 E-H, J).
There was no co-localization of nApoECFp17 with GFAP under similar experimental
conditions (Fig. 8 K-M).
To confirm whether the amino terminal fragment labeled by nApoECFp17
localizes to NFTs as opposed to plaques, double label experiments were conducted with
the two known tangle markers AT8 and PHF-1. The presence of nApoECFp17 was
present in fibrillary tangles, a subset of NFTs that were labeled by PHF-1. However,
nApoECFp17 also stained neurons that were negative for AT8 or PHF-1 (Fig. 9).
In a final set of experiments, we examined whether nApoECFp17 labeling occurs
together with MMP-9, an extracellular protease that was able to generate the predicted
~17 kDa fragment in vitro (Fig. 3C). As an initial approach, we screened representative
frontal cortex brain sections from AD subjects using bright-field microscopy in singlelabel experiments utilizing a human anti-MMP-9 monoclonal antibody. The presence of
MMP-9 was evident within plaque-rich regions in outer cortical layers and appeared to be
extracellular as expected (Fig. 10A and B). Next, double-label confocal
immunofluorescence experiments were undertaken using the same MMP-9 antibody
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together with nApoECFp17. In this case, although there was no co-localization between
the two antibodies, the two markers did occur within close proximity to one another
raising the possibility that MMP-9 may cleave apoE4 in vivo (Fig. 10C-E).
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DISCUSSION
Harboring the APOE4 allele increases risk for AD, however, despite exhaustive
efforts, the mechanism responsible for enhanced risk of harboring this allele remains
elusive. What separates apoE4 from the other isoforms (E3 and E2) is that apoE4 is more
susceptible to proteolysis and produces fragments that are neurotoxic in nature [19, 34,
35]. In order to identify these fragments in the human AD brain, we designed a sitedirected cleavage antibody targeting position D151 of full-length mature form of human
apoE4. In vitro, this antibody, which we have termed the nApoECFp17 antibody,
specifically labels an amino-terminal fragment of apoE4 of the correct predicted
molecular weight of ~17 kDa fragment following cleavage at position D151. Most
importantly, nApoECFp17 does not interact with full-length apoE4 or E3. Generation of
this amino-terminal fragment and recognition by nApoECFp17 was only observed with
recombinant apoE4 and not E3 following digestion with Type I collagenase. In addition,
immunoprecipitation pull-down experiments using the nApoECFp17 antibody revealed a
~17 kDa fragment that was detected by a commercial antibody whose epitope was
located at the extreme amino-terminus of full-length apoE4. Mass spectrometry of the
~17 kDa fragment indicated a 77% sequence coverage of amino acids 1-151 of apoE4.
That the epitope for the nApoCFp17 antibody is at the C-terminal end of this aminoterminal fragment was confirmed following synthesis of ApoE4 1-151 protein fragments.
A 6X histidine (His) tag was incorporated either at the N- or C-terminal end of ApoE41151 to

facilitate purification from E. coli. ELISA and Western blot results indicated that
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the nApoECFp17 antibody was only able to recognize ApoE41-151 in which the His tag
was attached to the amino-terminal end. Additional experiments in situ using postmortem
frontal cortex brain sections confirmed the specificity of the nApoECFp17 antibody.
These immunohistochemical experiments included showing co-localization of
nApoECFp17 within NFTs and not plaques. Previous studies emphasize this concept of
amino-terminal fragments localizing specifically with NFTs while carboxyl-terminated
fragments contribute to AD pathology in aiding in the formation of NFTs, but localize to
plaques only [19, 22, 23]. Moreover, labeling by nApoECFp17 was prevented following
preadsorption experiments with the peptide corresponding to the upstream sequence
(RKRLLRD) that would be generated following cleavage of apoE4 at position D151.
ApoE is primarily synthesized and secreted from astrocytes and microglia [15],
but surprisingly, nApoECFp17 strongly labeled nuclei of glial cells as well as NFTs.
These data suggest that the nApoECFp17 labeled fragment is being cleaved
extracellularly then taken up by microglia. The amino terminal end of apoE4 includes the
low-density lipoprotein (LDL) binding domain for full-length apoE because the receptor
binding region of apoE is 134-151 [15, 19]. The preferential interaction of apoE4 to the
LDL receptor is due to the arginine at position 112 [44], however the low-density
lipoprotein receptor protein (LRP) in the same family as the LDL receptor and undergoes
rapid and constitutive endocytosis. LRP has been suggested to mediate the neuronal
uptake of cholesterol and other lipids including apoE. The amino-terminal fragment
produced following cleavage at position D151 may interact with the low-density LRP
binding region and be taken up by microglia through receptor mediated endocytosis and
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trafficked to the nucleus. The function of this fragment in nucleus of microglia requires
further research, but one possible role could be to alter gene expression.
The final important result from these experiments is that collagenases and MMPs
are potential proteases capable of cleaving apoE4 or E3. Although the preferential
proteolysis of apoE4 versus E3 and E2 has been well documented, the exact nature of the
protease(s) involved in this process has not been definitively identified. In our hands,
MMP-1 and collagenase produced high-molecular weight complexes in vitro following
incubation with recombinant apoE4 that were identified following Western blot analysis
with nApoECFp17. Similar experiments utilizing active MMP-9 were of particular
interest because it produced the predicted ~17 kDa fragment recognized by nApoECFp17
following Western blot analysis. Additionally, in the AD brain, nApoECFp17-labeled
nuclei of microglia were identified in the same areas of the extracellular MMP-9 labeling
(in plaque-rich regions), which is consistent with where microglia are typically found.
These data support previous findings showing increased extracellular levels of MMP-9 in
AD [38] and the breakdown and loss of the integrity of the blood-brain barrier associated
with AD [45].
Together, the results from my thesis suggest a novel role for an amino-terminal
fragment found in the AD brain. The work from my thesis sets up the stage for further
research into the mechanism by which apoE4 fragments may be affecting AD
pathogenesis. The novel finding of the nApoECFp17 labeled amino-terminal fragment
localizing in the nuclei of microglia offers opportunities to study how this fragment may
be affecting gene expression. Currently, our lab is continuing to analyze how this
fragment is internalized through the LRP or LDL receptors using a microglial cell line.
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Since full-length apoE4 has been thought to traffic to the nucleus and up or down
regulate various gene expression such as genes associated with apoptosis, proinflammatory cytokines, and microtubule assembly [46], analysis of RNA sequence data
may shed light into how this fragment affects either signaling pathways or the APOE4
gene itself. The heightened risk associated with inheritance of the APOE4 allele has been
hypothesized to stem from the susceptibility of apoE4 to proteolysis more than the E3 or
E2 forms. Moreover, the enhanced susceptibility of apoE4 to proteolysis suggests apoE4
loses function or gains toxic functions that contribute to AD pathology, but
mechanistically remain unexplained. By understanding proteases that are involved in the
cleavage of apoE4 and how the resulting fragments affect cells in the brain, it could
ultimately be determined how the fragments affect cell signaling pathways or gene
expression and establish the role of apoE4 in late-onset AD pathology.
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FIGURES

Figure 1:

Synthesis of the nApoECFp17 antibody
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Figure 2:
ELISA: Verification of the polyclonal site-directed cleavage antibody
ApoE4 titers in immunized rabbits. Pre-immune rabbit serum (red line) measured at an
absorbance of 450 nm at dilutions from 1:250-1:32,000. And the immunized rabbit serum
(blue line) confirms the high titer of n ApoECFp17 antibody in sera from immunized
rabbits.
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Figure 3:
Characterization of a novel site-directed cleavage antibody to
fragmented apoE4. (A): Preincubation of human recombinant apoE4 but not apoE3 with
Type I collagenase for 1.5 hours at 37°C results in the generation of a 17 kDa fragment
recognized by affinity-purified nApoECFp17 antibody (lane 2) following Western blot
analysis. The right panel depicts the transferred gel slab that was stained with Coomassie
blue revealing full-length apoE4 and E3 (34 kDa) as well as the associated fragmentation
pattern following incubation with Type I collagenase. (B): Immunoprecipitation
experiment with the nApoECFp17 antibody following incubation of full-length apoE4
with Type I collagenase revealed the presence of a ~17 kDa band on a Coomassie gel
(left panel) that resulted in an immunoreactive band by Western blot using an animoterminal specific antibody to apoE4 (arrowhead, right panel). (C) Identical experiments
as in Panel A with the exception that purified collagenase (lane 2), MMP-1 (lanes 3 and
5), or MMP-9 (lane 4) were incubated with recombinant apoE4 (see methods and
materials for details). Incubation of apoE4 with either purified collagenase as well as
MMP-1 resulted in the presence of high-molecular weight bands detected by
nApoECFp17 following Western blot analysis, while incubation of MMP-9 resulted in
the detection of a 17 kDa band similar to that generated by Type I collagenase. MMP-1
generated a detectable band only when the apoE4 concentration was doubled (compare
lanes 3 vs. 5). In both A and C note the specificity of the nApoECFp17 for cleaved
fragments of apoE4 while no reactivity to full-length apoE was observed.

30

Figure 4:
Specificity of nApoECFp17 to the amino terminal of ApoE 1-151. (A)
ELISA assays in which 96-well plates were coated overnight at 4°C with either ApoE41151 with the His tag attached to the C-terminal end (red line), or with the His tag attached
to the N-terminal end (blue line). The results indicated that the nApoECFp17 antibody
only recognized ApoE51-151 in which the His tag was attached to the N-terminal end.
(B) Similar experiments as in Panel A were performed using Western blot analysis. In
this case, the nApoECFp17 antibody preferentially immunolabeled the apoE4 fragment in
which the His-tag was localized to the amino-terminal end (Right panel). The left panel
shows the identical experiment in utilizing an anti-His antibody that easily labeled both
protein fragments regardless of the location of the His tag.
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Figure 5:
Incubation of apoE3 with MMP-9 generates high-molecular weight
bands. Full-length recombinant apoE3 or apoE4 was incubated with activated MMP-9
for 24 hours at 37° C and reactions were terminated by the addition of 5X sample buffer.
Protein samples were separated on 15% SDS-PAGE gels, transferred to nitrocellulose,
and the probed with the nApoECFp17 antibody overnight at 1:500. The Ctl lane is full
length apoE3 protein incubated in the absence of MMP-9.

32

Figure 6:
Detection of fragmented apoE in the frontal cortex of the Alzheimer’s
disease brain. Representation bright-field staining in AD frontal cortex tissue sections
following application of the nApoeCFp17 antibody. Low (A) and high (B) magnification
of neurons llustrate the apparent loss of cell body integrity in the majority of neurons
labeled with the nApoECFp17 antibody. Staining was also observed in neuropil threads
within plaque-rich regions (C), along blood vesses (D), and the strongest labeling was
within small circular structures throughout both gray and white matter (E). All scale bars
represent 10 µm.
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Figure 7:
Specificity of the nApoECFp17 antibody labeling in the Alzheimer’s
disease brain. (A and B): Serial AD frontal cortex sections were immunolabeled with
immunized serum (A) or preimmune serum (B) with specific staining only observed
following application of immunized serum. Arrows in Panel A point to stained nuclei
following application of immunized serum. (C and D): Serial AD frontal cortex sections
were incubated with nApoECFp17 antibody alone (C), or following preadsorption with
the peptide used as an immunogen (D). Staining was largely prevented following
preadsorption with peptide (D). (E): Relative lack of labeling by nApoECFp17 in a
representative neuropathologically normal case. (F): Panel (i) depicts quantitative results
of the number of nApoECFp17-labeled nuclei in neuropathologically normal cases (NPN,
green bars, N=3) and in AD cases (red bars, N=9) following staining of frontal cortex
sections with nApoECFp17. For each case, the number of labeled nuclei was counted in a
40X field (N=3 fields, ±SEM). The data indicated a significant increase in the number of
nuclei labeled in AD cases (p= .0004). Panel (ii) illustrates quantitative analysis of the
number of nApoECFp17-positive nuclei (per 40 µm field, 3 different fields, ±SEM) in
specific APOE allele AD cases (N=2). Although higher numbers of nApoECFp17positive nuclei were observed for the APOE 4/4 group as compared to the other
genotypes, a significant difference (p<0.5) was only observed following comparison of
the APOE 4/4 group to 3/4.
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Figure 8:
Nuclear localization of an N-terminal fragment of apoE within
microglia of the AD brain. (A-D): Representative images from confocal
immunofluorescence in AD utilizing the nuclear stain, DAPI, (A), nApoECFp17 (B), the
microglial specific marker, Iba1 (C), with the overlap image shown in (D). Note the
strong nuclear localization of the nApoECFp17 antibody (arrow) within labeled
microglia. (E-H): Identical to Panels A-D with the exception that the oligodendrocyte
marker, Olig-1, was employed to specifically label oligodendrocytes. (I-J):
Quantification of microglia (I) or oligodendrocytes (J) double-labeled with nApoECFp17
indicated co-localization in 80% and 27.5% of microglia and oligodendrocytes,
respectively. Data show the number of Iba1- or Olig-1-labeled cells alone (blue bars),
number of nApoECFp17-labeled nuclei (green bars), and the number of cells with both
antibodies (red bars) identified in a 40X field within frontal cortex AD sections by
immunofluorescence microscopy (n = 3 fields for 3 different AD cases). (K-M): In
contrast to the nuclear localization of nApoECFp17 within microglia and
oligodendrocytes, confocal immunofluorescence double-label experiments with
nApoECFp17 and the astrocytic marker, GFAP, failed to produce any co-localization
between these two markers. Scale bars K-M represent 10 µm.
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Figure 9:
Localization of an amino-terminal fragment of ApoE within a subset
of NFTs of the AD brain. (A-F) Confocal immunofluorescence double-labeling in
representative frontal cortex sections of the AD brain utilizing the nApoECFp17 antibody
(green), the tangle marker AT8 (red), and the overlap image showed in (F), but not in the
majority of neurons labeled with nApoECFp17 (C). (G-H) Identical to panels A-F with
the exception that the mature tangle marker PHF-1 (red) was used. A subset of fibrillar
NFTs showed strong co-localization of the nApoECFp17 and PHF-1 (arrowhead I) in
contrast to AT8 labeling. The blue fluorescence in Panels F and I represent the nuclear
stain, DAPI.
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Figure 10:
Regional co-localization of extracellular MMP-9 surrounding
nApoECFp17 labeled neurons in the AD brain. (A-B) Representative bright field
microscopy in AD frontal cortex brain sections in single label experiments utilizing an
antibody to MMP-9 labeling gray matter at low magnification (A) and high magnification
(B). Localization appeared to occur in extracellular plaque-rich regions. (C-E) Confocal
immunofluorescence double-labeling in representative frontal cortex sections of the AD
brain utilizing nApoECFp17 (green), MMP-9 (red) reveal regional localization of the two
antibodies, but not co-localization in the merged image (E).
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TABLES
Table 1:

Case Demographics

Group
Age (yrs)
AD
71
AD
61
AD
80
AD
83
AD
75
AD
65
AD
76
AD
77
AD
77
NPN
74
NPN
65
NPN
67
NPN= neuropathologically normal

Sex
M
F
F
F
F
F
M
F
F
F
F
F

Cause of death
AD
AD
Dehydration
Cardiac Arrest
AD
AD
AD
Cardiac Arrest
Sepsis
Cancer
Cardiac Arrest
Heart Failure

APOE Genotype
3/3
3/4
4/4
3/3
3/4
N/A
3/3
N/A
4/4
N/A
N/A
N/A
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